Amerikaanse aandelen« Terug naar discussie overzicht

1. RW1963 7 april 2022 17:04

   auteur info

   •    RW1963

     Lid sinds: 16 apr 2015

     Laatste bezoek: 14 jul 2024

   •    Aanbevelingen

     Ontvangen: 1324

     Gegeven: 9933

   •    Aantal posts: 6.301

   Het wil hier ook maar niet vlotten
2. Mr sponge 7 april 2022 18:01

   auteur info

   •    Mr sponge

     Lid sinds: 16 jan 2001

     Laatste bezoek: 17 dec 2024

   •    Aanbevelingen

     Ontvangen: 555

     Gegeven: 178

   •    Aantal posts: 2.453

   Toch lijkt de koers mooi te stuiteren tussen de $4,25 en de $5,-
   Dat bied kansen....
   Ik ben normaal niet zo van het traden. Maar deze trend is wel heel duidelijk.
   Steeds klappen van 10% omhoog en dan langzaam terug zakken.
3. DeZwarteRidder 10 augustus 2023 16:47

   auteur info

   •    DeZwarteRidder

     Lid sinds: 29 jun 2012

     Laatste bezoek: 18 dec 2024

   •    Aanbevelingen

     Ontvangen: 23545

     Gegeven: 10399

   •    Aantal posts: 101.201

   Is Amyris failliet.....???
4. DeZwarteRidder 10 augustus 2023 16:49

   auteur info

   •    DeZwarteRidder

     Lid sinds: 29 jun 2012

     Laatste bezoek: 18 dec 2024

   •    Aanbevelingen

     Ontvangen: 23545

     Gegeven: 10399

   •    Aantal posts: 101.201

   ja hoor:
   
   +++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
   AMYRIS ANNOUNCES OPERATIONAL AND FINANCIAL RESTRUCTURING TO ADVANCE STRATEGIC TRANSFORMATION
   
   News provided by
   Amyris, Inc.
   
   09 Aug, 2023, 21:38 ET
   
   Voluntary Chapter 11 Commenced to Finalize Consensual Go-Forward Plan for Amyris' Core Business
   
   $190 Million Financing Commitment from Foris Ventures to Support Day-to-Day Operations
   
   EMERYVILLE, Calif., Aug. 9, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS) ("Amyris" or the "Company"), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it is moving forward with an operational and financial restructuring to further advance its ongoing strategic transformation and position the Company for long-term success.
   
   The restructuring is intended to improve the Company's cost structure, capital structure, and liquidity position while streamlining Amyris' business portfolio to focus on its core competencies in R&D and the scale-up, commercialization, and applications development of its sustainable ingredients derived through biofermentation.
   
   To facilitate the restructuring, Amyris and certain of its domestic subsidiaries commenced voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court for the District of Delaware (the "Court"). Its entities outside the U.S. are not included in the proceedings.
   
   In tandem, to advance the Company's restructuring goals and maximize the value of its assets, Amyris is planning to exit its consumer brands and will begin marketing them for sale, with a view to having these brands continue to leverage Amyris' cutting-edge science and technology while under new ownership. As the sale process progresses, Amyris will continue to operate these brands, including through retail partners and the brands' e-commerce platforms.
   
   Amyris has secured a commitment from an entity affiliated with existing lender Foris Ventures for $190 million of debtor-in-possession ("DIP") financing to support continued day-to-day operations as the Company works with its key stakeholders to negotiate a consensual go-forward plan centered on Amyris' core capabilities. Subject to Court approval and the DIP budget, this DIP financing will provide liquidity to help fulfill commitments to the Company's valued employees, customers, partners, and vendors during the process.
   
   "Since its founding 20 years ago, Amyris has been a pioneer in the development of ingredients made with synthetic biology and has enjoyed great commercial success, particularly as a result of our innovative Lab-to-Market™ technology platform, proven ability to rapidly bring new products to market, and state-of-the-art science and manufacturing infrastructure," said Han Kieftenbeld, Interim Chief Executive Officer and Chief Financial Officer of Amyris. "Over the past months, we have been hard at work on a strategic transformation plan to reduce costs, improve operational effectiveness, and achieve sustainable growth. We believe the step forward our company has taken today puts us on the best path to address our financial challenges and achieve a comprehensive solution – rooted in Amyris' ground-breaking science, formulation capabilities, and technology."
   
   Mr. Kieftenbeld added, "Our aspiration to become the most efficient and productive biotechnology company in our industry has not changed. We remain incredibly excited about Amyris' long-term potential and our uniquely talented team's proven ability to deliver on the promise of synthetic biology and continue to make a lasting impact. At the end of this restructuring process, we believe that Amyris will emerge as a financially stronger company with a more focused business model and well-defined path to profitability. In turn, we will be poised to grow sustainably alongside our valued partners and make an even greater impact on our world through clean chemistry."
   
   To ensure a smooth transition into Chapter 11, the Company filed with the Court a series of customary motions seeking to continue operating as usual and uphold its commitments to its employees and other valued stakeholders during the process. These "first day" motions include requests to continue to pay wages and provide benefits to employees as usual and maintain its customer programs and policies. The Company intends to pay vendors in the ordinary course for all goods received and services rendered after the filing.